{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:03:18Z","timestamp":1791849798879,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nihon MediPhysics, Co., Ltd.","award":["Collaboration Research"],"award-info":[{"award-number":["Collaboration Research"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Although beta-amyloid (A\u03b2) positron emission tomography (PET) images are interpreted visually as positive or negative, approximately 10% are judged as equivocal in Alzheimer\u2019s disease. Therefore, we aimed to develop an automated semi-quantitative analysis technique using <jats:sup>18<\/jats:sup>F-flutemetamol PET images without anatomical images.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Overall, 136 cases of patients administered <jats:sup>18<\/jats:sup>F-flutemetamol were enrolled. Of 136 cases, five PET images each with the highest and lowest values of standardized uptake value ratio (SUVr) of cerebral cortex-to-pons were used to create positive and negative templates. Using these templates, PET images of the remaining 126 cases were standardized, and SUVr images were produced with the pons as a reference region. The mean of SUVr values in the volume of interest delineated on the cerebral cortex was compared to those in the CortexID Suite (GE Healthcare). Furthermore, centiloid (CL) values were calculated for the 126 cases using data from the Centiloid Project (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.gaain.org\/centiloid-project\">http:\/\/www.gaain.org\/centiloid-project<\/jats:ext-link>) and both templates. <jats:sup>18<\/jats:sup>F-flutemetamol-PET was interpreted visually as positive\/negative based on A\u03b2 deposition in the cortex. However, the criterion \"equivocal\" was added for cases with focal or mild A\u03b2 accumulation that were difficult to categorize. Optimal cutoff values of SUVr and CL maximizing sensitivity and specificity for A\u03b2 detection were determined by receiver operating characteristic (ROC) analysis using the visual evaluation as a standard of truth.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SUVr calculated by our method and CortexID were highly correlated (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.9657). The 126 PET images comprised 84 negative and 42 positive cases of A\u03b2 deposition by visual evaluation, of which 11 and 10 were classified as equivocal, respectively. ROC analyses determined the optimal cutoff values, sensitivity, and specificity for SUVr as 0.544, 89.3%, and 92.9%, respectively, and for CL as 12.400, 94.0%, and 92.9%, respectively. Both semi-quantitative analyses showed that 12 and 9 of the 21 equivocal cases were negative and positive, respectively, under the optimal cutoff values.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This semi-quantitative analysis technique using <jats:sup>18<\/jats:sup>F-flutemetamol-PET calculated SUVr and CL automatically without anatomical images. Moreover, it objectively and homogeneously interpreted positive or negative A\u03b2 burden in the brain as a supplemental tool for the visual reading of equivocal cases in routine clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-022-01769-x","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T17:02:58Z","timestamp":1657645378000},"page":"865-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Etsuko","family":"Imabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Tamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuho","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Kamitaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-0072","authenticated-orcid":false,"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2967\/jnumed.106.037762","volume":"48","author":"S Ng","year":"2007","unstructured":"Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer\u2019s disease. J Nucl Med. 2007;48:547\u201352.","journal-title":"J Nucl Med"},{"key":"1769_CR2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00259-010-1382-8","volume":"37","author":"T Suotunen","year":"2010","unstructured":"Suotunen T, Hirvonen J, Immonen-R\u00e4ih\u00e4 P, Aalto S, Lisinen I, Arponen E, et al. Visual assessment of 11C-PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging. 2010;37:1141\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1769_CR3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00259-016-3591-2","volume":"44","author":"T Yamane","year":"2017","unstructured":"Yamane T, Ishii K, Sakata M, Ikari Y, Nishio T, Ishii K, et al. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer\u2019s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging. 2017;44:850\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1769_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s12149-015-0978-2","volume":"29","author":"C Namiki","year":"2015","unstructured":"Namiki C, Takita Y, Iwata A, Momose T, Senda M, Okubo Y, et al. Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer\u2019s disease. Ann Nucl Med. 2015;29:570\u201381.","journal-title":"Ann Nucl Med"},{"key":"1769_CR5","doi-asserted-by":"publisher","first-page":"20181020","DOI":"10.1259\/bjr.20181020","volume":"92","author":"D Fakhry-Darian","year":"2019","unstructured":"Fakhry-Darian D, Patel NH, Khan S, Barwick T, Svensson W, Khan S, et al. Optimisation and usefulness of quantitative analysis of 18F-florbetapir PET. Br J Radiol. 2019;92:20181020.","journal-title":"Br J Radiol"},{"key":"1769_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s00259-020-05044-x","volume":"48","author":"JY Kim","year":"2021","unstructured":"Kim JY, Oh D, Sung K, Choi H, Paeng JC, Cheon GJ, et al. Visual interpretation of 18F-Florbetaben PET supported by deep learning-based estimation of amyloid burden. Eur J Nucl Med Mol Imaging. 2021;48:1116\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. 18F-Flutemetamol amyloid-beta PET imaging compared with 11C-PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:290\u2013300.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.nicl.2015.10.007","volume":"9","author":"JM Mountz","year":"2015","unstructured":"Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of qualitative and quantitative imaging characteristics of 11C-PiB and 18F-flutemetamol in normal control and Alzheimer\u2019s subjects. Neuroimage Clin. 2015;9:592\u20138.","journal-title":"Neuroimage Clin"},{"key":"1769_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2967\/jnumed.118.211532","volume":"60","author":"LE Collij","year":"2019","unstructured":"Collij LE, Konijnenberg E, Reimand J, Kate MT, Braber AD, Lopes Alves I, et al. Assessing amyloid pathology in cognitively normal subjects using 18F-flutemetamol PET: comparing visual reads and quantitative methods. J Nucl Med. 2019;60:541\u20137.","journal-title":"J Nucl Med"},{"key":"1769_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00259-019-04595-y","volume":"47","author":"HJ Son","year":"2020","unstructured":"Son HJ, Oh JS, Oh M, Kim SJ, Lee JH, Roh JH, et al. The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases. Eur J Nucl Med Mol Imaging. 2020;47:332\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1769_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12149-019-01420-2","volume":"34","author":"Y Okada","year":"2020","unstructured":"Okada Y, Kato T, Iwata K, Kimura Y, Nakamura A, Hattori H, et al. Evaluation of PiB visual interpretation with CSF A\u03b2 and longitudinal SUVr in J-ADNI study. Ann Nucl Med. 2020;34:108\u201318.","journal-title":"Ann Nucl Med"},{"key":"1769_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00259-015-3067-9","volume":"42","author":"P Payoux","year":"2015","unstructured":"Payoux P, Delrieu J, Gallini A, Adel D, Salabert AS, Hitzel A, et al. Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging. 2015;42:1459\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1769_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315.","journal-title":"Alzheimers Dement"},{"key":"1769_CR14","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"1769_CR15","first-page":"3","volume":"8","author":"G Klein","year":"2021","unstructured":"Klein G, Delmar P, Kerchner GA, Hofmann C, Abi-Saab D, Davis A, et al. Thirty-Six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab. J Prev Alzheimers Dis. 2021;8:3\u20136.","journal-title":"J Prev Alzheimers Dis"},{"key":"1769_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/alz.12069","volume":"16","author":"I Lopes Alves","year":"2020","unstructured":"Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, et al. Quantitative amyloid PET in Alzheimer\u2019s disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020;16:750\u20138.","journal-title":"Alzheimers Dement"},{"key":"1769_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.578753","volume":"11","author":"H Matsuda","year":"2021","unstructured":"Matsuda H, Ito K, Ishii K, Shimosegawa E, Okazawa H, Mishina M, et al. Quantitative evaluation of 18F-flutemetamol PET in patients with cognitive impairment and suspected alzheimer\u2019s disease: a multicenter study. Front Neurol. 2021;11: 578753.","journal-title":"Front Neurol"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2967\/jnumed.118.207811","volume":"60","author":"J Lilja","year":"2019","unstructured":"Lilja J, Leuzy A, Chiotis K, Savitcheva I, S\u00f6rensen J, Nordberg A. Spatial normalization of 18F-flutemetamol PET images using an adaptive principal-component template. J Nucl Med. 2019;60:285\u201391.","journal-title":"J Nucl Med"},{"key":"1769_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118775","volume":"246","author":"L Iaccarino","year":"2022","unstructured":"Iaccarino L, La Joie R, Koeppe R, Siegel BA, Hillner BE, Gatsonis C, et al. rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. Neuroimage. 2022;246: 118775.","journal-title":"Neuroimage"},{"key":"1769_CR20","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1088\/0031-9155\/61\/15\/5768","volume":"61","author":"G Akamatsu","year":"2016","unstructured":"Akamatsu G, Ikari Y, Ohnishi A, Nishida H, Aita K, Sasaki M, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys Med Biol. 2016;61:5768\u201380.","journal-title":"Phys Med Biol"},{"key":"1769_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G","volume":"7","author":"J Ashburner","year":"1999","unstructured":"Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999;7:254\u201366.","journal-title":"Hum Brain Mapp"},{"key":"1769_CR22","doi-asserted-by":"crossref","unstructured":"Mattoccia S, Tombari F, Di Stefano L. Reliable rejection of mismatching candidates for efficient ZNCC template matching. 15th IEEE International Conference on Image Processing. 2008;849\u221252.","DOI":"10.1109\/ICIP.2008.4711888"},{"key":"1769_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8","volume":"10","author":"JL Lancaster","year":"2000","unstructured":"Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, et al. Automated talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000;10:120\u201331.","journal-title":"Hum Brain Mapp"},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"Suppl 1","key":"1769_CR25","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/j.neurobiolaging.2014.04.033","volume":"36","author":"P Bourgeat","year":"2015","unstructured":"Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159\u201366.","journal-title":"Neurobiol Aging"},{"key":"1769_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neuroimage.2012.12.014","volume":"70","author":"P Edison","year":"2013","unstructured":"Edison P, Carter SF, Rinne JO, Gelosa G, Herholz K, Nordberg A, et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage. 2013;70:423\u201333.","journal-title":"Neuroimage"},{"key":"1769_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:22.","journal-title":"Alzheimers Res Ther"},{"key":"1769_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nicl.2018.04.022","volume":"19","author":"Y Su","year":"2018","unstructured":"Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, et al. Utilizing the centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin. 2018;19:406\u201316.","journal-title":"Neuroimage Clin"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-022-01769-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T18:43:23Z","timestamp":1664304203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-022-01769-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s12149-022-01769-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"6 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were approved by the Ethics Committee of the Tokyo Metropolitan Institute of Gerontology (Approved number: R21-041).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}